PSMA PET/MRI Outperforms mpMRI in Biochemically Recurrent Prostate Cancer
Positron emission tomography/magnetic resonance imaging using 68Ga-Prostate Specific Membrane Antigen (PSMA)-HBED-CC (PSMA PET/MRI) has a higher positive rate and sensitivity than standard multiparametric magnetic resonance imaging (mpMRI) in patients with biochemically recurring prostate cancer, found a study published online October 11, 2021, in Translational Oncology.
Highlights presented by primary author Juana Martinez, et. al., were:
“PSMA PET/MRI has a higher true positive rate and sensitivity than mpMRI in patients with biochemically recurrent prostate cancer.
“The true positive rate for PSMA PET/MRI was significantly greater in patients who were post prostatectomy for primary treatment.
“40% of patients with a PSA value less than 0.2 ng/mL had a positive PSMA PET/MRI read compared to 9% on MRI.”
“We conclude that PSMA PET/MRI is a robust imaging modality with higher sensitivity than multiparametric MRI alone for the detection of biochemical recurrence. Together, this combined imaging modality is a powerful tool which can aid in not only the detection of the abnormal lesion, but also guide in treatment planning. In patients who are being evaluated for biochemical recurrence and require imaging, PSMA PET/MRI should be recommended for restaging and treatment planning,” wrote the team.
Juana Martinez, Kritika Subramanian, Daniel Margolis, Elisabeth O’Dwyer, Joseph Osborne, Yuliya Jhanwar, Himanshu Nagar, Nicholas Williams, Arindam RoyChoudhury, Gabriela Madera, John Babich, Sandra Huicochea Castellanos. 68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study. Translational Oncology. 2022 Volume 15, Number 1. Available online October 11, 2021, at https://www.sciencedirect.com/science/article/pii/S1936523321002345?via%3Dihub. Accessed October 25, 2021.